Zymeworks, Inc.
1385 West 8th Avenue
Suite 540
Vancouver
British Columbia
V6H 3V9
Canada
Tel: 604-678-1388
Website: http://www.zymeworks.com/
Email: info@zymeworks.com
About Zymeworks, Inc.
Established in 2003 with offices in Vancouver, BC and Seattle, WA, Zymeworks is a fast-growing, clinical-stage biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. Zymeworks is proud to have active collaborations with Merck, Eli Lilly, Celgene, GlaxoSmithKline, Daiichi-Sankyo, Johnson & Johnson, Leo Pharma and BeiGene and is committed to making a meaningful difference in the lives of patients everywhere.
257 articles about Zymeworks, Inc.
-
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
6/2/2023
Jazz Pharmaceuticals plc and Zymeworks Inc. presented positive pivotal trial data, including new data on progression-free survival, from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers.
-
Zymeworks Announces Participation in Upcoming June 2023 Investor Conferences
6/1/2023
Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced that management will participate in the following upcoming investor conferences.
-
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
5/18/2023
Zymeworks Inc. today announced the departure of Neil Klompas, President and Chief Operating Officer.
-
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
5/8/2023
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2023 and provided a summary of recent business highlights.
-
Zymeworks Announces Participation in Upcoming Investor Conferences - May 1, 2023
5/1/2023
Zymeworks Inc. today announced that management will participate in the following upcoming investor conferences.
-
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
4/18/2023
Zymeworks Inc. announced 11 presentations including new data from its clinical and preclinical development-stage programs at the 2023 American Association for Cancer Research Annual Meeting being held in Orlando, Florida.
-
Zymeworks To Host First Quarter 2023 Results Conference Call
4/17/2023
Zymeworks Inc. today announced that management will report its first quarter 2023 financial results after market close on May 8, 2023.
-
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
4/10/2023
Zymeworks Inc. today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023.
-
Zymeworks Announces Participation in Upcoming April 2023 Investor Conferences
4/3/2023
Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced that management will participate in the following upcoming investor conferences: 2023 Bloom Burton & Co. Healthcare Investor Conference.
-
Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting
3/14/2023
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 – 19, 2023.
-
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
3/7/2023
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a summary of recent business highlights.
-
Zymeworks Announces Participation in Upcoming Investor Conferences - February 28, 2023
2/28/2023
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences.
-
Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call
2/21/2023
Zymeworks Inc. today announced that management will report its fourth quarter and full year 2022 financial results after market close on March 7th, 2023.
-
Zymeworks Announces Participation in Upcoming Investor Conferences - January 25, 2023
1/25/2023
Zymeworks Inc. today announced that management will participate in the following upcoming investor conferences.
-
Jazz Pharmaceuticals and Zymeworks announced results from a Phase II trial of the latter’s HER2-targeted antibody for metastatic gastroesophageal adenocarcinoma.
-
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
1/19/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced tolerability and efficacy results, including the first overall survival (OS) data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
-
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
1/4/2023
Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced updated key strategic priorities and provided updated financial guidance for the 2023 calendar year.
-
Jazz Pharmaceuticals exercised its option on Zymeworks' promising anti-cancer agent.
-
Zymeworks Announces Participation in Upcoming Investor Conference - December 21, 2022
12/21/2022
Zymeworks Inc. today announced that management will participate in an upcoming investor conference.
-
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
12/21/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks' zanidatamab.